Is Biocon making a comeback?
Finshots Daily
00:00
Complex diseases, Biologics, and Biocon's biosimilars business
This chapter explores the complex world of biologics and biosimilars, discussing Biocon's strategy in developing these complex proteins to treat diseases like cancer and diabetes. It also touches on the challenges faced by Biocon, such as delays in approvals and concerns about corporate governance.
Play episode from 04:19
Transcript
